Developmental toxicity testing of monoclonal antibodies: an enhanced pre- and postnatal study design option.
For many monoclonal antibodies (mAb), the preferred species for general and reproductive safety testing is often the cynomolgus monkey. This article describes the rationale for combining the traditional "segmented" embryofetal development study with the pre- and postnatal development (PPND) study into a single "enhanced" PPND study design in the cynomolgus monkey where a single cohort of animals is exposed throughout gestation and allowed to give birth naturally. The proposed "enhanced" PPND study design evaluates all the stages of the traditional two study design using fewer animals. It also assesses the functional consequences of mid to late gestational exposure. This is of particular relevance to the risk assessment of monoclonal antibodies where fetal exposure to maternal IgG increases as pregnancy progresses and where morphologic examination of a pre-term fetus may not be adequate to reveal the presence of adverse effects on functional development of key target organs.
Stewart
Jane
J
Safety Assessment, AstraZeneca Pharmaceuticals, Macclesfield, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK. jane.stewart@astrazeneca.com
D023401:Animal Use Alternatives; D000818:Animals; D000831:Animals, Newborn; D000911:Antibodies, Monoclonal / Q000633:toxicity*; D047108:Embryonic Development / Q000187:drug effects; D005260:Female; D047109:Fetal Development / Q000187:drug effects; D008252:Macaca fascicularis; D018811:Maternal Exposure; D008431:Maternal-Fetal Exchange / Q000187:drug effects; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects / Q000139:chemically induced*; D012098:Reproduction / Q000187:drug effects*; D012107:Research Design; D018675:Toxicity Tests / Q000379:methods*
D000911:Antibodies, Monoclonal